Tongyuankang Pharmaceutical-B (02410) plans to issue a total of 76 million subscribed shares to Qilu and CVG Global

According to Zhitong Finance App, Tongyuankang Pharmaceutical-B (02410) announced that on November 12, 2026, the Company entered into separate subscription agreements with these subscribers (Qilu and CVG Global). Qilu and CVG Global have conditionally agreed to subscribe, and the Company has conditionally agreed to allocate and issue 57 million H shares to Qilu and CVG Global at the subscription price of HK$3.80 per subscription share.

The subscription price of HK$3.80 is approximately 7.32% off of the closing price of HK$4.100 per H share reported on the Stock Exchange on November 12, 2026 (the last trading day).

The total proceeds from the subscription process amounted to HK$288.8 million. After deducting professional fees and other related expenses payable by the Company in connection with the subscription matters, the net proceeds from the subscription were approximately HK$288 million (equivalent to approximately RMB 247 million), or approximately 60% of the net proceeds, or approximately HK$173 million, for TY-0540 phase II and phase III clinical trials for platinum-resistant ovarian cancer as a single agent; approximately 30% of the net proceeds, or approximately HK$86.53 million, for TY-0540 combined with fluvizicrin to treat CDK4/6 drug-resistant breast cancer; Approximately 10% of income The net amount, or approximately HK$28.84 million, was used for working capital and general corporate purposes.

Equity investments indicate that these subscribers acknowledge the company's long-term growth potential. Proceeds from the subscription will provide additional capital support for the Company and will be used for the Company's overall business operations.

The directors believe that the relevant terms of the subscription matter are fair and reasonable, and that the transactions to be carried out under it conform to the overall interests of the Company and its shareholders.